The UK guidelines also recommend the introduction of the term HER2-low in histopathology reports for 1+ and 2+ non-amplified breast cancers after approval of the use of ADCs for HER2-low breast cancer has been granted. This evidence concerns the gene ERBB2 and breast carcinoma.